Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new ...
Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results